

01-28-07

0420

(4)


1626

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Please type a plus sign (+) inside this box → ☐**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/021,780		
	Filing Date	December 7, 2001	
	First Named Inventor	Anantanarayan	
	Group Art Unit	Unknown	
	Examiner Name	Unknown	
Total Number of Pages in This Submission	7	Attorney Docket Number	3015/6/US

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard 77 References Form PTO 1449
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT


Firm or Individual name	David M. Gryte Harness, Dickey & Pierce, P.L.C.
Signature	
Date	January 9, 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: January 9, 2002

Typed or printed name	Lana B. Ekiss		
Signature		Date	January 9, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Attorney Docket No. 3015/6US
HDP Docket No. 6794-000032/COA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Anantanarayan et al.

Serial No.: 10/021780

Filed: December 7, 2001

Art Unit: Unknown

Examiner: Unknown

For: Substituted Pyrazoles as p38 Kinase Inhibitors

Attorney
Docket No.: 3015/6US

INFORMATION DISCLOSURE STATEMENT

BOX IDS
Commissioner of Patents and Trademarks
Washington, D.C. 20231

Dear Sir/Madam:

To comply with 37 CFR 1.97 and 1.98, a copy of Form PTO-1449 and copies of the documents listed on it are enclosed.

In accordance with MPEP 609 and 707.05(b), Applicant respectfully requests that each document listed be given thorough consideration and that the Examiner cite each document of record in the prosecution history of the present application by initialing Form PTO-1449 next to each document. Applicant requests such initialing even if the Examiner does not consider: (1) a listed document to be sufficiently pertinent to use in a rejection; (2) a document to be prior art for any reason; or (3) that the guidelines for citation have been fully complied with respecting a particular document. Applicant makes this request so that each document becomes cited on the face of a patent issuing on the present application.

Applicant submits the present Information Disclosure Statement in compliance with the duty to disclose information material to patentability under 37 CFR 1.56, but by listing such documents Applicant is not admitting that such documents are necessarily relevant or prior art.


Applicant intends no representation that the listed documents represent the results of a complete search. Applicant anticipates that the Examiner, in the normal course of examination, will make an independent search consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of such search, will review for relevance every document listed on the attached Form even if not initialed.

Applicant makes no representation as to the accuracy of any translation provided with this Information Disclosure Statement.

Applicant solicits early and favorable consideration.

Applicant believes there are no fees due in connection with the filing of this Information Disclosure Statement. If, however, there is ever a deficiency, please charge any fees to our Deposit Account No. 08-0750.

Dated: 1-9-02

Respectfully submitted,
BY: 
David M. Gryte
Reg. No. 41,809
Attorneys for Applicant
Harness, Dickey & Pierce, P.L.C.
7700 Bonhomme, Suite 400
St. Louis, MO 63105
Telephone: (314) 726-7500
Facsimile: (314) 726-7501

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited in the United States Postal Service as first class mail addressed to: Commissioner for Patents, Washington, D.C. 20231 on January 9, 2002.

Lana B. Ellis

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

3015/6/US

SERIAL NO.

10/021780

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Anantanarayan et al.

FILING DATE

12/07/01

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1	3,254,093	05/1966	Huisgen et al.	260	295	
	2	3,984,431	10/1976	Gueremy et al.	260	310	
	3	4,000,281	12/1976	Beiler et al.	424	263	
	4	5,051,518	09/1991	Murray et al.	548	373	
	5	5,134,142	07/1992	Matsuo et al.	514	255	
	6	5,559,137	09/1996	Adams et al.	514	341	
	7	5,486,534	01/1996	Lee et al.	514	406	
	8	5,589,439	12/1996	Goto et al.	504	261	
	9	5,658,903	08/1997	Adams et al.	514	235.8	
	10	5,739,143	04/1998	Adams et al.	514	275	
	11	5,756,529	05/1998	Isakson et al.	514	406	
	12	5,972,972	10/1999	Mihelich et al.	514	341	
	13	5,998,425	12/1999	Adams et al.	514	275	

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	14	WO 83/00330	02/1983	PCT				
	15	WO 92/19615	11/1992	PCT				
	16	WO 95/06036	03/1995	PCT				
	17	WO 95/22545 A1	08/1995	PCT				
	18	WO 96/03385 A1	02/1996	PCT				

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449
(REV. 7-80)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

3015/6/US

SERIAL NO.

10/021780

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Anantanarayan et al.

FILING DATE

12/07/01

GROUP


19	WO 96/21452 A1	07/1996	PCT				
20	WO 96/21654 A1	07/1996	PCT				
21	WO 96/40143 A1	12/1996	PCT				
22	WO 97/01551	01/1997	PCT				
23	WO 97/23479 A1	07/1997	PCT				
24	WO 97/25046 A1	07/1997	PCT				
25	WO 97/25047 A1	07/1997	PCT				
26	WO 97/25048 A1	07/1997	PCT				
27	WO 97/32583 A1	09/1997	PCT				
28	WO 97/35855 A1	10/1997	PCT				
29	WO 97/35856 A1	10/1997	PCT				
30	WO 97/47618 A1	12/1997	PCT				
31	WO 98/07425 A1	02/1998	PCT				
32	WO 98/16230 A1	04/1998	PCT				
33	WO 98/25619 A1	06/1998	PCT				
34	WO 98/52937 A2 & A3	11/1998	PCT				
35	WO 98/52940 A1	11/1998	PCT				
36	WO 98/52941 A1	11/1998	PCT				
37	WO 98/57966 A1	12/1998	PCT				
38	WO 99/01130 A1	01/1999	PCT				
39	WO 99/01131 A1	01/1999	PCT				
40	WO 99/01136 A1	01/1999	PCT				

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

3015/6/US

SERIAL NO.

10/021780

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Anantanarayan et al.

FILING DATE

12/07/01

GROUP

41	WO 99/01452 A1	01/1999	PCT				
42	WO 99/17776 A1	04/1999	PCT				
43	WO 99/32121 A1	07/1999	PCT				
44	WO 99/61426 A1	12/1999	PCT				
45	0 115 640 A2	12/1983	EPO				
46	0 418 845 A1	03/1991	EPO				
47	0 515 041 A2	11/1992	EPO				
48	0 531 901 A2	03/1993	EPO				
49	4-145081	05/1992	JAPAN				X
50	5-17470	01/1993	JAPAN				X
51	5-345772	12/1993	JAPAN				X
52	8-183787	07/1996	JAPAN				X
53	WO 94/19350	09/1994	PCT				
54	WO 95/31451	11/1995	PCT				
55	0 846 686 A1	06/1998	EPO				
56	0 846 687 A1	06/1998	EPO				
57	DD 295 374 A5	10/1991	GERMANY				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

58	Boehm, J.C. et al., "New Inhibitors Of p38 Kinase", Exp. Opin. Ther. Patents, Vol. 10(1), pp. 25-36, (2000).
59	Laszlo, S.E. et al., "Pyrroles And Other Heterocycles As Inhibitors Of p38 Kinase", <i>Bioorganic & Medicinal Chemistry Letters</i> 8, pp. 2689-2694, 1998.
60	Dannhardt G. et al., "ω-Aminopropyl-pyrazole durch Ringtransformation von Enaminonen der Pyrrolidinreihe", Arch. Pharm., Vol. 321, No. 1, pp. 17-19, 1988.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

61	Zheng-Nian Huang, "Synthesis and Biological Activities of 1-(substituted pyrazol-4-yl)-1,2,4-triazoles", <i>Chemical Abstracts</i> , Volume 124, No. 23, Abstract No. 317062d, 1996.
62	Chemical Abstracts, 13 th Collective Chemical Substance Index 1992-1996, Book 51, pp. 546-550.
63	Zhengming, Li et al., "Syntheses of Di-heterocyclic Compounds; Pyrazolyimidazoles And Isoxazolyimidazoles", <i>Heteroatom. Chem.</i> , Vol. 9, No. 3, pp. 317-320, 1998.
64	Zheng-Nian Huang, "The Reaction Of α -OXO- α -Triazolyketene Dithioacetal With Amines, Hydrazine And Guanidine", <i>Chinese Chemical Letters</i> , Vol. 5, No. 1, pp. 31-34, 1994.
65	Popova, A.N. et al., "Synthesis Of 4-(Pyrazol-4-yl)-Substituted Salts Of Pyrylium And Pyridines", <i>Chemical Abstracts</i> , Vol. 098, No. 1, January 3, 1983, Abstract No. 004498.
66	Bauer, V.J. et al., "4-3(5)-Pyrazolyl Pyridinium Salts. A New Class Of Hypoglycemic Agents", <i>J. Med. Chem.</i> , Vol. 11; pp. 981-4, (September 1968)
67	Cativiela, C. et al., "On the Synthesis Of 3(5)-(Carbomethoxy)-4-hetarylpyrazoles", <i>J. Heterocycl. Chem.</i> , Vol. 25; pp. 851-5, (May-June 1988)
68	Fischer, U. et al., "1,3-Dipolar Additions To 7-Methylthieno [2,3-c]pyridine 1,1-dioxide", <i>Helv. Chim. Acta</i> ; Vol. 63(6), No. 180, pp. 1719-27, (1980)
69	September 24, 1998 PCT International Search Report (PCT/US98/10436)
70	Badger, Alison M. et al., "Disease-Modifying Activity Of SB 242235, A Selective Inhibitor Of p38 Mitogen-Activated Protein Kinase, In Rat Adjuvant-Induced Arthritis", <i>Arthritis & Rheumatism</i> , Vol. 43, No. 1, pp. 175-183, 2000.
71	Henry, James R., "p38 Mitogen-Activated Protein Kinase As A Target For Drug Discovery", <i>Drugs of the Future</i> , Vol. 24, pp. 1345-1354, 1999.
72	Salituro, F.G. et al., "Inhibitors of p38 MAP Kinase: Therapeutic Intervention Cytokine-Mediated Diseases", <i>Current Medicinal Chemistry</i> , Issue 6, pp. 807-823, 1999.
73	Liverton, N.J. et al., "Design And Synthesis Of Potent, Selective, And Orally Bioavailable Tetrasubstituted Imidazole Inhibitors Of p38 Kinase Mitogen-Activated Protein Kinase", <i>J. Med. Chem.</i> , Vol. 42, pp. 2180-2190, 1999.
74	Adams, J.L. et al., "Pyrimidinylimidazole Inhibitors Of CSBP/p38 Kinase Demonstrating Decreased Inhibition Of Hepatic Cytochrome p450 Enzymes", <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 8, pp. 3111-3116, 1998.
75	Gallagher, T.F., "Regulation Of Stress-Induced Cytokine Production By Pyridinylimidazoles; Inhibition Of CSBP Kinase", <i>Bioorganic & Medicinal Chemistry</i> , Vol. 5, pp. 49-64, 1997.
76	Hanson, G.J., "Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis", <i>Exp. Opin. Ther. Patents</i> , Vol. 7, pp. 729-733, 1997.
77	Moerck R.E. et al., "Pyrazole Addition To Δ^1 -Azirines. Structure of Purported 2:1 Adducts of Δ^1 -Azirines With sym-Tetrazines", <i>J.Chem. Soc., Chem. Commun.</i> , No. 19, pp. 782-783 (1974).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.